Nearly one out of every 20 staff in the FDA offices that oversee drugs and biologics are gone after the Trump administration ...

The US Customs and Border Protection warns drugmakers against misrepresenting product values to evade import rules ahead of ...

President Donald Trump unofficially asked CMS Administrator Mehmet Oz to lead the administration’s talks with drugmakers to ...

CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

Kura Oncology said one-quarter of patients with certain forms of advanced acute myeloid leukemia went into complete remission ...

Gilead's Trodelvy shows significant improvement in progression-free survival for metastatic triple-negative breast cancer ...

Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, stepped down as CFO of the New York biotech ...

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least ...

After a median 34.2 months of follow-up, patients taking Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex survived for a median of 34 months, compared to 27 months for those ...

The White House released its first MAHA Commission report, detailing some of the Trump administration’s top priorities for ...

The House of Representatives on Thursday passed President Donald Trump’s tax cut package, with steep Medicaid cuts, PBM ...

FDA Commissioner Marty Makary defended thousands of staff cuts during his first congressional hearing since taking office, ...